Finland (FI)
Finland (fi)

Accuracy and
reliability

The FreeStyle Libre 3 system delivers outstanding

performance and improves clinical outcomes 

FreeStyle Libre 2 system
FreeStyle Libre 2 system
FreeStyle Libre 2 system

Consensus Error Grid for the FreeStyle Libre 3 system compared
with reference4

MARD=mean absolute relative difference; YSI=Yellow Springs
Instruments; glucose sensing technology reliability defined by
signal connection.

The only CGM with
sub-8% overall MARD1-3

The FreeStyle Libre 3 system is accurate3, stable and
consistent over 14 days – no finger pricks5, no user
calibration, no code entry.

  • 7.8% overall MARD1 – the lower the MARD, the more
    accurate the results.

  • 93.3% within ±20% and 93.4% within ±20%. Percentage
    of readings within ±20 mg/dL of YSI values for glucose
    levels <70 mg/dL and ±20% when ≥70 mg/dL1

  • 99.9% in zones A and B of Consensus Error Grid1

Excellent accuracy in the low through
high glucose ranges3

YSI Plasma venous blood glucose reference using the YSI 2300 STAT PLUS Glucose and Lactate Analyzer

Overall 

performance3

Accuracy

                    

FreeStyle Libre 3 system accuracy study

FreeStyle Libre 3 Accuracy Study, ATTD 2022 Commercial Symposium

5x more readings power up to 5x faster alarms6

With readings every minute, the FreeStyle Libre 3 system provides 5x faster readings and alarms6 than other
leading brands and is the most reliable CGM for signal strength.7,8

5x more readings power up to 5x faster alarms

Example: Glucose is dropping at 3mg/dL per minute. The low glucose alarms is set at 70 mg/dL.

FreeStyle Libre 3 - Empowerment Every Minute, ATTD 2022 Commercial Symposium

The FreeStyle Libre 3 system outperforms other CGMs on connectivity7

The FreeStyle Libre 3 system delivers performance your patients can count on – so they won't miss a low glucose
alarm8 or possible hypo.

Strongest Bluetooth integration7

10-meter range is more than 50% further than other CGMs7.

Longest data storage9

15-day data storage makes data gaps a thing of the past.

Improved clinical outcomesφ,10-12

With outstanding accuracy,3 best-in-class connectivity7 and readings every minute, patients can act faster to
reduce hypoglycaemia and improve overall glucose control10-14.

Figure Hab1c

FreeStyle Libre 2 significantly
reduced time spent below target
range (<70 mg/dL) by 43 minutes
per day in people with T1D10

Figure Hab1c

Reduces nocturnal hypoglycaemia
in T2D (<70 mg/dL, time in hour,
from 11:00 pm to 6:00 am)
(p<0.0001)11

Figure Hab1c

Reduces serious hypoglycaemia in
T2D (<55 mg/dL, time in hour, within
24 hours)
(p<0.0014)11

Figure Hab1c

0.55% average reduction in A1c

observed at 2-4 months, sustained 

for 12 months13,14

Figure Hab1c

People with T1D increased their time
in range by more than 2 hours per
day using FreeStyle Libre 2
compared to SMBG10

Clinical benefits of continuous glucose monitoring

CGM Accuracy & Performance, ATTD 2022 Commercial Symposium

The FreeStyle Libre 3 system delivers outstanding accuracy3, reliability and clinical benefits

Outstanding accuracy across
multiple measures, including
strong low-end performance3

Figure Hab1c

Real-time readings updated
every minute—5x faster than
any other CGMs15

Figure Hab1c

Significant improvement in
clinical outcomes10-12, φ

Learn more about the FreeStyle Libre 3 digital ecosystem

FreeStyle Libre 3 system

FreeStyle Libre 3 App

LibreLinkUp

LibreView

φStudies data are collected with the FreeStyle Libre system or FreeStyle Libre 2 system and is applicable to the FreeStyle Libre 3 system based on technological similarities.

* Data on file, Abbott Diabetes Care, Inc. Based on the number of users worldwide for the FreeStyle Libre portfolio compared to the number of users for other leading personal use sensor-based glucose monitoring systems.

References & Disclaimers

  1. FreeStyle Libre 3 User Manual. FreeStyle Libre 3 demonstrates 7.8% overall MARD with 7.5% adult MARD and 8.6% pediatric MARD (age 6-17) in accuracy to YSI reference.
  2. Comparison based on publicly available information. Data on file, Abbott Diabetes Care, Inc.
  3. Alva, S. et al. Diabetes Ther. (2023); doi: 10.1007/s13300-023-01385-6.
  4. Data on file, Abbott Diabetes Care, Inc.
  5. Finger pricks are required when glucose readings and alarms do not match symptoms or expectations.
  6. Dexcom G6 CGM User Guide and Medtronic Guardian Connect System User Guide.
  7. Data on file. Abbott Diabetes Care, Inc. Based on the signal strength in Dexcom G7 CGM User Guide and Medtronic Guardian Connect System User Guide.
  8. Notifications will only be received when alarms are turned on and the sensor is within 10 meters unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts. See the FreeStyle Libre 3 User’s Manual for more information.
  9. Data on file. Abbott Diabetes Care, Inc. Based on the data storage in Dexcom G7 CGM User Guide and Medtronic Guardian Connect System User Guide.
  10. Leelarathna, L. et al. N Engl J Med (2022): https://doi.org/10.1056/NEJMoa2205650.
  11. Haak, T. et al. Diabetes Ther. (2017): https://doi.org/10.1007/s13300-016-0223-6.
  12. Yaron, M. et al. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166.
  13. Evans, M. et al. Diabetes Ther (2020): https://doi.org/10.1007/s13300-019-00720-0.
  14. NOTE: statistically significant A1c reduction based on the confidence interval range.
  15.  Based on the reading frequency in Dexcom G7 CGM User Guide and Medtronic Guardian Connect System User Guide compared to readings every minute for FreeStyle Libre 3 system sensors.
Error 500 Modal
Myfreestyle Landing Page
Myfreestyle Landing Page Secure
Login Page
Miksi FreeStyle Libre -järjestelmä?
FREESTYLE-VALIKOIMA
Tutkimus & koulutus
Uutiset & tapahtumat
TUKI
Abbott

© 2025 Abbott. All Rights Reserved. Sensorin ulkokuori, FreeStyle, Libre ja niihin liittyvät tavaramerkit ovat Abbottin tavaramerkkejä. Muut tavaramerkit ovat omistajiensa omaisuutta. Abbottin tällä sivustolla olevia tavaramerkkejä, tuotenimiä ja mallisuojia ei saa käyttää ilman Abbottin ennalta antamaa kirjallista valtuutusta muuhun kuin Abbottin tuotteiden tai palveluiden tunnistamiseen.

Tämä sivusto ja tiedot on tarkoitettu käytettäväksi Suomessa asuville henkilöille. FreeStyle Libre Flash -glukoosinseurantajärjestelmä, FreeStyle Libre 2 Flash -glukoosinseurantajärjestelmä, FreeStyle Libre 3 -jatkuva glukoosinseurantajärjestelmä, FreeStyle LibreLink -sovellus, FreeStyle Libre 3 -sovellus, FreeStyle LibreLink Special Edition -sovellus, LibreLinkUp -sovellus ja LibreView -pilvipalvelu ovat CE -merkattuja lääkinnällisiä laitteita.

FreeStyle Lite- ja FreeStyle Freedom Lite -verenglukoosin seurantajärjestelmät, FreeStyle Precision Neo -verenglukoosin ja ketoaineen seurantajärjestelmä, FreeStyle Lite-, FreeStyle Precision -verenglukoosin mittausliuskat ja FreeStyle Precision -veren β-ketoaineen mittausliuskat ovat CE -merkattuja in vitro diagnostisia lääkinnällisiä laitteita.

CE 2797. Valmistaja: Abbott Diabetes Care Ltd., Range Road, Witney, Oxon, OX29 OYL, UK. Tuotekuvia käytetään vain havainnollistamistarkoituksessa, eikä niissä ole todellisia potilaita, potilastietoja tai hoitohenkilökuntaa. Abbott Oy, Karvaamokuja 2A, 00380 Helsinki. ADC-75458 v2.0 11/23

Haluatko poistua tältä sivulta?

Alla oleva "Kyllä"-linkki vie sinut muulle kuin Abbott Laboratories -sivustolle. Linkit muille verkkosivustoille eivät ole Abbott Laboratoriesin hallinnassa, eikä Abbott Laboratories ole vastuussa tällaisten verkkosivustojen sisällöstä tai sellaisista linkeistä. Abbott Laboratories tarjoaa nämä linkit sinulle vain avuksi, eikä minkään linkin lisääminen tarkoita, että Abbott Laboratories hyväksyy sivuston.

Haluatko poistua tältä sivulta?

Sivusto on tarkoitettu Suomessa työskenteleville terveydenhuollon ammattilaisille.

Tämä on tuotekohtainen verkkosivusto, joka on tarkoitettu vain terveydenhuollon ammattilaisille Suomessa. Jos asut toisessa maassa, ota yhteyttä paikalliseen Abbott-toimistoon saadaksesi maatasi koskevat oikeat tuotetiedot.